Medicines & supplements – Current GIS Alerts 2026
Found 735 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
MEGAPAR FORTE
An error in the leaflet incorrectly specifies the maximum dose, which may lead to overdose and poses a real risk to patients’ health or life. Potential effects: paracetamol poisoning, liver damage, serious complications, life‑threatening condition.
APHTIN
Non-compliant product odor and a decrease in active substance content were found, not meeting quality specifications. Potential effects: lack of treatment efficacy, possible adverse effects related to product degradation.
SYMBELLA
The product does not meet specification requirements for the amount of ethinylestradiol released within 15 minutes, which may affect contraceptive efficacy. Potential effects: reduced effectiveness, risk of unplanned pregnancy.
RANIGAST PRO
This risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product, which may affect human health and life. Potential effects: poisoning, carcinogenic effects.
RANIGAST MAX
The risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product, which may affect human health and life and potentially endanger patients’ life or health. Potential effects: carcinogenic effects, liver damage, other toxic effects.
SOLVERTYL
Suspicion of the presence of N-nitrosodimethylamine (NDMA) contamination in medicinal products with Ranitidinum, which may affect human health and life and poses a potential risk to patients. Potential effects: poisoning, carcinogenic effects, systemic complications.
RANIMAX TEVA
The risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in this medicinal product, which may affect human health and life. Potential effects: increased risk of carcinogenic effects and serious threat to patients’ health and life.
RANIGAST
This risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product, which may affect human health and life. Potential effects: possible carcinogenic effect, liver damage, other toxic complications.
RANIGAST
The risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product, which may affect human health and life. Potential effects: possible carcinogenic and other toxic effects, risk to health and life.
RANIGAST FAST
This risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product, which may affect human health and life. Potential effects: possible carcinogenic effects and other serious health disorders.
RANIC
This risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product containing ranitidine, which may affect human health and life. Potential effects: possible carcinogenic effects, liver damage, poisoning.
RANIBERL MAX
Suspected presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product, which may affect human health and life. Potential effects: carcinogenic action, organ damage with long-term exposure.
RIFLUX
Suspected presence of N-nitrosodimethylamine (NDMA) contamination in medicinal products containing ranitidine, which may affect human health and life due to the potential toxic effects of this substance. Potential effects: possible toxic effects, complications, health risk.
RANITYDYNA AUROVITAS
Suspected presence of N-nitrosodimethylamine (NDMA) contamination in medicinal products containing Ranitidinum, which may affect human health and life, posing a potential risk to patients. Potential effects: poisoning, carcinogenic effects, serious health complications.
BICAVERA Z 1,5% GLUKOZĄ I WAPNIEM 1,25 MMOL/L
Potential quality defect of the primary packaging, which may affect the safety and quality of the peritoneal dialysis solution. Potential effects: complications during dialysis, infections, lack of treatment efficacy.
IBUFEN DLA DZIECI FORTE O SMAKU TRUSKAWKOWYM
A quality defect consisting of an out-of-specification result for the ibuprofen content parameter in the medicinal product Ibufen for children Forte, strawberry flavour. Potential effects: lack of treatment efficacy or overdose leading to adverse reactions.
BENZACNE
A defective internal lacquer coating was found on the inner surface of the primary packaging (tube) used for packing the medicinal product, creating a substantiated potential risk to patients’ health or life. Potential effects: health complications, possible loss of medicine quality or safety.
ZOLAXA RAPID
A quality defect was found: an out-of-specification result for the active substance content per tablet, which may mean an incorrect dose of the medicine for the patient. Potential effects: lack of treatment efficacy or increased adverse effects.
FOSIDAL O SMAKU POMARAŃCZOWYM
It was found that the risk of using products containing fenspiride is disproportionate to their therapeutic effect, with a potential threat to patients’ health or life. Potential effects: serious adverse reactions, complications and life‑threatening events.
FOSIDAL O SMAKU MALINOWYM
A risk of use disproportionate to the therapeutic effect of the product containing fenspiride was identified, which may pose a real and highly probable threat to patients’ health or life. Potential effects: treatment complications, serious adverse reactions, threat to health or life.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.